Trending...
- Blackstone Griddle Black Friday & Cyber Monday (2023): Review of Latest Griddle Offers Reported by Deal Tomato
- Woburn Dentistry Provides Comprehensive Perio Procedures From One Convenient Location
- Away Travel Luggage Cyber Monday (2023): Round-up of Latest Offers Published by Deal Stripe
~ PhenomeX Inc., a functional cell biology company listed on the Nasdaq (CELL), has announced that it will be showcasing its latest optofluidic and proteomic technologies at two upcoming cell biology conferences.
At the Discovery on Target 2023 conference, held from September 25-27 in Boston, Genovac, a long-standing customer of PhenomeX and super user of the Beacon optofluidic technology, will lead a presentation featuring PhenomeX's Beacon platform. The presentation is entitled "Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization" and will be delivered by Andreas Weise, senior account manager at Genovac.
The Annual Festival of Biologics Basel Conference & Exhibition will also feature PhenomeX's optofluidic and proteomic technologies in booth #910. Jonathan Didier, senior field applications scientist at PhenomeX, will present "Rapid Discovery of Clinically Relevant Antibodies using the PhenomeX Beacon" as part of the Cell Culture & Upstream Processing conference track. Additionally, a poster presentation entitled "Rapid Discovery of Functional Human Memory B Cell-Derived Antibodies for SARS-CoV-2 Using the Beacon Optofluidic System" will be featured.
More on Boston Chron
PhenomeX is dedicated to advancing human health through its unique suite of high-throughput tools and services that offer unparalleled resolution and speed to accelerate discoveries that can profoundly improve the prevention and treatment of disease. Its award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. The company is also in the process of changing its name; all inquiries regarding Phenomenex, Inc. should be directed to their website.
At the Discovery on Target 2023 conference, held from September 25-27 in Boston, Genovac, a long-standing customer of PhenomeX and super user of the Beacon optofluidic technology, will lead a presentation featuring PhenomeX's Beacon platform. The presentation is entitled "Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization" and will be delivered by Andreas Weise, senior account manager at Genovac.
The Annual Festival of Biologics Basel Conference & Exhibition will also feature PhenomeX's optofluidic and proteomic technologies in booth #910. Jonathan Didier, senior field applications scientist at PhenomeX, will present "Rapid Discovery of Clinically Relevant Antibodies using the PhenomeX Beacon" as part of the Cell Culture & Upstream Processing conference track. Additionally, a poster presentation entitled "Rapid Discovery of Functional Human Memory B Cell-Derived Antibodies for SARS-CoV-2 Using the Beacon Optofluidic System" will be featured.
More on Boston Chron
- Mayor Wu Announces $1 Million in New Grant Funding to Support the Revitalization of Boston's Restaurant Industry
- Allotex Announces New Investor and Expansion of Production Facilities USA - English USA - English
- Green Office Partner Launches Managed Print Services Program in Canada
- GLCPS Sponsors Two Students to Attend Brown University Leadership Institute
- Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion
PhenomeX is dedicated to advancing human health through its unique suite of high-throughput tools and services that offer unparalleled resolution and speed to accelerate discoveries that can profoundly improve the prevention and treatment of disease. Its award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. The company is also in the process of changing its name; all inquiries regarding Phenomenex, Inc. should be directed to their website.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Unveiling a Secluded Paradise: Beachfront Home on Dog Island, Carrabelle, Florida, Goes to Auction
- ASICS Teams Up with BlueConic for Enhanced Personalization and Data Privacy Compliance
- SalonInteractive Launches in Square App Marketplace to Provide eCommerce, Marketing & More to Beauty Professionals
- RacquetX Announces Miami Open Experience as Excitement Builds for Landmark 2024 Event
- Malta Closes Funding to Deploy Its Long-Duration Energy Storage System
- Dominating Business Intelligence: Informer Tops the BI & Analytics Survey for the Fourth Time
- IDC FutureScape: The Digital Business Era Has Arrived, Augmented by GenAI
- Mayor Wu Shares Boston's Winter Weather Preparations
- Labthink Introduces Cutting-Edge C406H: A Revolutionary Combination OTR and WVTR Tester
- You won't believe these amazing stories from our guest authors!
- St. Joseph's/Candler Fast Tracks Implementation of MEDITECH Expanse Ambulatory Across 100+ Providers
- Advcash adds instant Pix payments in Brazil
- Floris United Methodist Church announces first-ever mission trip for people with disabilities
- Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
- Sip Social Co. Partners With Omnify To Streamline User Experience Across Growing Operations
- City of Boston Celebrates Grand Opening of 250 Centre Street
- Fred Nassiri Relaunches "Love Sees No Colour"
- TKO Miller Advises Visu-Sewer on its Partnership With Fort Point Capital
- Vicinity Energy Steams Ahead to Sustainable Future with Arrival of 42MW Electric Boiler in Cambridge, Mass.
- Investing in Boston's Adult Learners: Adult Literacy Initiative